The impact of histologic tumor response on survival of patients treated with neoadjuvant mFOLFOX6 plus bevacizumab for the synchronous liver metastases from colorectal cancer.

被引：3
|
作者：
Katayose, Yu
Ishida, Kazuyuki
Nakagawa, Kei
Yamauchi, Junichiro
Oikawa, Masaya
Sakurai, Naoki
Musha, Hiroaki
Shimamura, Hiromune
Miura, Koh
Motoi, Fuyuhiko
Egawa, Shinichi
Unno, Michiaki
机构：
[1] Tohoku Univ, Grad Sch Med, Div Integrated Surg & Oncol, Sendai, Miyagi 980, Japan
[2] Iwate Med Univ, Dept Mol Diagnosit Pathol, Morioka, Iwate 020, Japan
[3] Sendai Kousei Hosp, Sendai, Miyagi, Japan
[4] Sendai Open Hosp, Sendai, Miyagi, Japan
[5] Yamagata Prefectural Cent Hosp, Yamagata, Japan
[6] Tohoku Rosai Hosp, Sendai, Miyagi, Japan
[7] Sendai Med Ctr, Sendai, Miyagi, Japan
[8] Tohoku Univ, Grad Sch Med, Div Hepatobiliary & Pancreat Surg, Sendai, Miyagi 980, Japan
[9] Tohoku Univ, Grad Sch Med, Dept Surg, Sendai, Miyagi 980, Japan
[10] Tohoku Univ, Int Res Inst Disaster Sci, Sendai, Miyagi 980, Japan
[11] Tohoku Univ, Sch Med, Sendai, Miyagi 980, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.625
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
625
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
    Loupakis, F.
    Schirripa, M.
    Caparello, C.
    Funel, N.
    Pollina, L.
    Vasile, E.
    Cremolini, C.
    Salvatore, L.
    Morvillo, M.
    Antoniotti, C.
    Marmorino, F.
    Masi, G.
    Falcone, A.
    BRITISH JOURNAL OF CANCER, 2013, 108 (12) : 2549 - 2556
  • [22] A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
    Van Cutsem, E.
    Prenen, H.
    D'Haens, G.
    Bennouna, J.
    Carrato, A.
    Ducreux, M.
    Bouche, O.
    Sobrero, A.
    Latini, L.
    Staines, H.
    Oum'Hamed, Z.
    Dressler, H.
    Studeny, M.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2015, 26 (10) : 2085 - 2091
  • [23] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
    van Hazel, Guy A.
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Peeters, Marc
    Perez, David
    Robinson, Bridget A.
    Strickland, Andrew H.
    Ferguson, Tom
    Rodriguez, Javier
    Kroening, Hendrik
    Wolf, Ido
    Ganju, Vinod
    Walpole, Euan
    Boucher, Eveline
    Tichler, Thomas
    Shacham-Shmueli, Einat
    Powell, Alex
    Eliadis, Paul
    Isaacs, Richard
    Price, David
    Moeslein, Fred
    Taieb, Julien
    Bower, Geoff
    Gebski, Val
    Van Buskirk, Mark
    Cade, David N.
    Thurston, Kenneth
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1723 - +
  • [24] Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial
    Heinrich, Kathrin
    Heinemann, Volker
    Westphalen, Benedikt
    Oecal, Osman
    Van Hazel, Guy A.
    Gibbs, Peter
    Seidensticker, Max
    Ricke, Jens
    Seidensticker, Ricarda
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Survival of patients with liver metastases from colorectal cancer treated with bevacizumab and FOLFOX4
    Dzunic, Miljana
    Andjelkovic-Apostolovic, Marija
    Vrbic, Svetislav
    Pejcic, Ivica
    Petkovic, Ivan
    Cvetanovic, Ana
    Dinic, Sasa
    JOURNAL OF BUON, 2020, 25 (01): : 212 - 219
  • [26] FDG PET monitoring of neoadjuvant FOLFIRI plus bevacizumab treatment of potentially resectable liver metastases from colorectal cancer.
    Caraco, C.
    Aloj, L.
    Arrichiello, C.
    Di Gennaro, F.
    Nasti, G.
    Ottaiano, A.
    Romano, C.
    Izzo, F.
    Albino, V.
    Tatangelo, F.
    De Lutio, E.
    Iaffaioli, R. V.
    Perrone, F.
    Lastoria, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S279 - S279
  • [27] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER
    Graham, C. N.
    Hechmati, G.
    Hjelmgren, J.
    De Liege, F.
    Lanier, J.
    Knoof, A.
    Knox, H.
    Barber, B.
    de Pouvourville, G.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [28] HISTOPATHOLOGICAL RESPONSE TO FOLFOXIRI PLUS BEVACIZUMAB OF LIVER METASTASES FROM COLORECTAL CANCER
    Caparello, Chiara
    Loupakis, Fotios
    Schirripa, Marta
    Funel, Niccola
    Pollina, Luca
    Vasile, Enrico
    Cremolini, Chiara
    Salvatore, Lisa
    Masi, Gianluca
    Fornaro, Lorenzo
    Campani, Daniela
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2011, 22 : v95 - v95
  • [29] Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Hjelmgren, Jonas
    de Liege, Frederique
    Lanier, Julie
    Knox, Hediyyih
    Barber, Beth
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (16) : 2791 - 2801
  • [30] Neoadjuvant FOLFIRI plus bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial
    Nasti, G.
    Piccirillo, M. C.
    Izzo, F.
    Ottaiano, A.
    Albino, V.
    Delrio, P.
    Romano, C.
    Giordano, P.
    Lastoria, S.
    Caraco, C.
    di Castelguidone, E. de Lutio
    Palaia, R.
    Daniele, G.
    Aloj, L.
    Romano, G.
    Iaffaioli, R. V.
    BRITISH JOURNAL OF CANCER, 2013, 108 (08) : 1566 - 1570
12345